Newly released results from the phase III ADAURA trial reveal that osimertinib yielded a 5.5-year median disease-free survival in the post-surgical treatment of patients with EGFR-mutated lung cancer, and nearly three in four patients treated with adjuvant osimertinib were disease-free at four years.
GRAIL LLC presented final results from the interventional PATHFINDER study, which evaluated multi-cancer early detection screening using a blood test and the clinical care pathways following a “cancer signal detected” MCED test result in 6,662 individuals aged 50 years or older, an age group at elevated risk for cancer.
A new subgroup analysis across the MONALEESA phase III program found that patients with visceral metastases who were treated with Kisqali (ribociclib) plus endocrine therapy in the first-line setting achieved a median OS of 62.7 months compared to 52.1 months for those treated with endocrine therapy alone.
Long-term data from the phase III PRIMA study showing Zejula (niraparib) maintained a sustained and clinically meaningful PFS benefit as a maintenance therapy in patients with first-line ovarian cancer following a response to platinum-based chemotherapy. Importantly, this benefit was sustained across all biomarker subgroups, including BRCAm, HRd and HRp.
Giving standard chemotherapy drugs in a specific sequence for some types of metastatic breast cancer can help reduce overall costs and improve the value of care while preserving quality of life, according to a study led by UNC Lineberger Comprehensive Cancer Center and UNC Gillings School of Global Public Health researchers.
The Sarah Cannon Research Institute joined Strata Oncology Inc.’s Precision Indications for Approved THerapies (NCT05097599) trial.
The WiTT Group and Mary Crowley Cancer Research form partership to enhance access to clinical trials
The WiTT Group Inc., a company focused on solving the non-clinical challenges patients face as they go through cancer treatment, formed a partnership Mary Crowley Cancer Research to identify and help patients gain access to clinical trials.
Phase I/II ARROW trial results show that pralsetinib, a highly selective RET inhibitor, was well-tolerated and demonstrated robust, durable responses in patients with RET fusion-positive cancers regardless of tumor type.
Results from the phase III 006 Study of Cytalux (pafolacianine) injection for intraoperative imaging of folate receptor positive ovarian cancer reports that use of Cytalux during ovarian cancer surgery demonstrated identification of additional lesions that were not identified with conventional means and not otherwise planned for resection.
A study led by researchers at NCI demonstrated that older adults who participate weekly in many different types of leisure time activities, such as walking for exercise, jogging, swimming laps, or playing tennis, may have a lower risk of death from any cause, as well as death from cardiovascular disease and cancer.
